ZVRA: Zevra Therapeutics, Inc. Stock

by  •  • Comments Off on ZVRA: Zevra Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 460.95
Enterprise Value ($M) 483.70
Book Value ($M) 41.02
Book Value / Share 0.75
Price / Book 11.24
NCAV ($M) -50.11
NCAV / Share -0.92
Price / NCAV -9.20

Profitability (mra)
Return on Invested Capital (ROIC) -0.89
Return on Assets (ROA) -0.61
Return on Equity (ROE) -1.88

Liquidity (mrq)
Quick Ratio 2.93
Current Ratio 3.02

Balance Sheet (mrq) ($M)
Current Assets 81.57
Assets 172.71
Liabilities 131.69
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 23.61
Operating Income -87.00
Net Income -105.51
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -69.67
Cash from Investing -22.16
Cash from Financing 82.11

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Nantahala Capital Management, LLC 4.38
02-12 13G Adage Capital Management, L.P. 6.84
02-05 13G/A BlackRock, Inc. 7.60 69.29
11-14 13G Woodline Partners LP 7.70
11-12 13G/A Vanguard Group Inc 5.23 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2025-03-12 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-15 132,322 688,968 19.21
2025-05-14 288,797 1,538,269 18.77
2025-05-13 188,491 540,555 34.87
2025-05-12 61,986 407,085 15.23

(click for more detail)

Similar Companies
XERS – Xeris Biopharma Holdings, Inc. XLO – Xilio Therapeutics, Inc.
YMAB – Y-mAbs Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io